肠道微生物群与整个生命周期中的睡眠障碍
Gut microbiota on sleep disorders throughout the lifespan.
文献信息
| PMID | 42735570 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Zulun Zhang |
| 作者单位 | Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiang Jia Yuan, Nanjing, 210011, China; Jiangsu Engineering Research Center for Advanced Microbiota Medicine, Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China. |
| 期刊 | Microbiological research |
| SCI 分区 | Q1 |
| IF | 8.7 |
| 研究类型 | 综述 Meta · 临床 |
| 所属专科 | 鼻科 |
中文摘要
肠道微生物群在整个生命过程中经历动态变化，并在人类健康和疾病中发挥关键作用。研究表明，在不同生命阶段，多种微生物群-肠-脑轴相关疾病中均存在肠道微生物群紊乱，超越了传统医学学科的界限。本文综述了关于人类生命周期中肠道微生物群与睡眠障碍的文献，涵盖阻塞性睡眠呼吸暂停、昼夜节律睡眠障碍和失眠。肠道微生物群失调与儿童神经发育疾病、成人精神疾病和胃肠道疾病、老年人神经退行性疾病和心血管疾病共病的睡眠障碍有关。探讨了肠道微生物群通过免疫、神经和内分泌途径调节睡眠的机制。研究了基于微生物群的干预措施对睡眠障碍的治疗潜力，特别强调了在每個关键生命阶段益生菌和粪菌移植（FMT）的临床证据和争议。根据微生物疗法报告首选条目（PRIM）的最新指南，评估了FMT和益生菌治疗睡眠障碍的临床研究质量。在106项纳入研究中，根据PRIM标准，40.0%（6/15）的FMT研究和57.1%（52/91）的益生菌研究被归类为低质量研究（定义为PRIM评分<14）。本综述为促进睡眠障碍的微生物群基础研究和治疗策略的发展提供了未来方向。全面理解生命周期中睡眠障碍的微生物群-肠-脑轴对于开发个性化疗法具有变革性潜力。
英文摘要
The gut microbiota undergoes dynamic changes and plays a crucial role in human health and disease throughout life. Studies have revealed gut microbiota disruption in various microbiota‑gut‑brain axis‑related diseases at different life stages, transcending boundaries of traditional medical disciplines. This article reviews the literature on gut microbiota and sleep disorders throughout the human life cycle, encompassing obstructive sleep apnea, circadian rhythm sleep disorders, and insomnia. Gut microbiota dysbiosis has been implicated in sleep disorders comorbid with neurodevelopmental diseases in children, psychiatric and gastrointestinal diseases in adults, and neurodegenerative and cardiovascular diseases in the elderly. The mechanisms by which gut microbiota regulates sleep through the immune, neuronal, and endocrine pathways are explored. The therapeutic potential of microbiota‑based interventions for sleep disorders is investigated, with particular emphasis on clinical evidence and controversies regarding probiotics and fecal microbiota transplantation (FMT) at each critical life stage. The quality of clinical studies on FMT and probiotics for sleep disorders is assessed according to the latest guidelines of the preferred reporting items for microbiotherapy (PRIM). Of the 106 included studies, according to PRIM criteria, 40.0% (6/15) of FMT studies and 57.1% (52/91) of probiotic studies were classified as low‑quality research (defined as PRIM score < 14). This review provides future directions to facilitate the development of microbiota‑based research and therapeutic strategies for sleep disorders. A comprehensive understanding of the microbiota‑gut‑brain axis in sleep disorders across life stages holds transformative potential for the development of personalized therapies.